SAGE Therapeutics Inc. (SAGE)

165.33
NASDAQ : Health Technology
Prev Close 163.60
Day Low/High 161.42 / 165.78
52 Wk Low/High 79.88 / 193.56
Avg Volume 361.90K
Exchange NASDAQ
Shares Outstanding 51.65M
Market Cap 8.45B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Sage Therapeutics Announces Positive Results From Placebo-Controlled Trial In A Model Of Insomnia Demonstrating Activity On Sleep Parameters And Supporting Development Of SAGE-217 As Potential Treatment For Sleep Disorders

Sage Therapeutics Announces Positive Results From Placebo-Controlled Trial In A Model Of Insomnia Demonstrating Activity On Sleep Parameters And Supporting Development Of SAGE-217 As Potential Treatment For Sleep Disorders

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced positive results from a Phase 1/2,...

Sage Therapeutics To Provide Pipeline Update At J.P. Morgan Healthcare Conference And Outline Key 2018 Initiatives To Support Planned Evolution To A Fully-Integrated Commercial Biopharmaceutical Company

Sage Therapeutics To Provide Pipeline Update At J.P. Morgan Healthcare Conference And Outline Key 2018 Initiatives To Support Planned Evolution To A Fully-Integrated Commercial Biopharmaceutical Company

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that in a corporate presentation at the...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on January 2, 2018, the...

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 9, 2018

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 9, 2018

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company is scheduled to...

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Sage Therapeutics To Present At BMO Prescriptions For Success Healthcare Conference

Sage Therapeutics To Present At BMO Prescriptions For Success Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Sage will participate in a...

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers

The Cambridge, Mass.-based firm unveiled positive top-line results from its Phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder.

Sage Therapeutics Reports Positive Top-line Results From Phase 2 Placebo-Controlled Trial Of SAGE-217 In Major Depressive Disorder

Sage Therapeutics Reports Positive Top-line Results From Phase 2 Placebo-Controlled Trial Of SAGE-217 In Major Depressive Disorder

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced positive top-line results from the Phase...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on December 1, 2017, the...

Sage Therapeutics Announces Closing Of $345 Million Public Offering Of Common Stock, Including Full Exercise Of Option To Purchase Additional Shares

Sage Therapeutics Announces Closing Of $345 Million Public Offering Of Common Stock, Including Full Exercise Of Option To Purchase Additional Shares

Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the closing of its previously...

Sage Therapeutics Prices Public Offering Of Common Stock

Sage Therapeutics Prices Public Offering Of Common Stock

Sage Therapeutics (Nasdaq: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten...

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics Announces Proposed Public Offering Of Common Stock

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an...

Noteworthy Thursday Option Activity: SAGE, VIAV, KODK

Noteworthy Thursday Option Activity: SAGE, VIAV, KODK

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sage Therapeutics Inc , where a total volume of 23,211 contracts has been traded thus far today, a contract volume which is representative of approximately 2.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 551.4% of SAGE's average daily trading volume over the past month, of 420,980 shares.

The Dip Buyers Have Simply Been a Bit Slow

The Dip Buyers Have Simply Been a Bit Slow

But if they start to weaken, be ready to make some adjustments fast.

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

Sage Skyrockets on Postpartum Depression Drug Studies Data -- Biotech Movers

The Cambridge, Mass.based firm unveiled positive top-line results from a pair of Phase 3 studies of brexanolone in postpartum depression.

Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints In Both Phase 3 Clinical Trials In Postpartum Depression

Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints In Both Phase 3 Clinical Trials In Postpartum Depression

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced positive top-line results from two Phase...

Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., To Board Of Directors

Sage Therapeutics Appoints Asha Nayak, M.D., Ph.D., To Board Of Directors

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Asha Nayak, M.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on November 1, 2017, the...

Sage Therapeutics Announces Third Quarter 2017 Financial Results And Provides Pipeline Update

Sage Therapeutics Announces Third Quarter 2017 Financial Results And Provides Pipeline Update

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and...

Sage Therapeutics To Report Third Quarter 2017 Financial Results On Thursday, November 2, 2017

Sage Therapeutics To Report Third Quarter 2017 Financial Results On Thursday, November 2, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Therapeutics To Participate In Leerink Investor Conference

Sage Therapeutics To Participate In Leerink Investor Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will participate...

Alexion Could Target Sage, Ra Pharma: Analyst

Alexion Could Target Sage, Ra Pharma: Analyst

BMO Capital Markets analyst M. Ian Somaiya says Alexion could view Sage Therapeutics and Ra Pharmaceuticals as potential acquisition targets. Somaiya pointed to Sage's diverse pipeline and Ra's diversified complement pipeline.

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

The Lexington, Mass.-based company unveiled results from its Phase 2a study of ADX-102 in dry eye disease. Other biotech movers in premarket trading on Sept. 12 include Sage Therapeutics and Intercept Pharmaceuticals.

Sage Therapeutics Reports Top-Line Results From Phase 3 STATUS Trial Of Brexanolone In Super-Refractory Status Epilepticus

Sage Therapeutics Reports Top-Line Results From Phase 3 STATUS Trial Of Brexanolone In Super-Refractory Status Epilepticus

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported top-line results from its Phase 3...

Sage Therapeutics To Present At Morgan Stanley Healthcare Conference

Sage Therapeutics To Present At Morgan Stanley Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that Jeff Jonas, M.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on September 1, 2017, the...

Sage Therapeutics Announces Second Quarter 2017 Financial Results And Provides Pipeline Update

Sage Therapeutics Announces Second Quarter 2017 Financial Results And Provides Pipeline Update

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and...

Sage Therapeutics To Report Second Quarter 2017 Financial Results On Thursday, August 3, 2017

Sage Therapeutics To Report Second Quarter 2017 Financial Results On Thursday, August 3, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on July 3, 2017, the Compensation...

SAGE Crosses Above Average Analyst Target

In recent trading, shares of Sage Therapeutics Inc have crossed above the average analyst 12-month target price of $83.18, changing hands for $83.90/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

TheStreet Quant Rating: D (Sell)